|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
ATE159548T1
(de)
|
1990-11-13 |
1997-11-15 |
Immunex Corp |
Bifunktionelle wählbare fusionsgene
|
|
AU6953394A
(en)
|
1993-05-21 |
1994-12-20 |
Targeted Genetics Corporation |
Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
|
|
US5814618A
(en)
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
|
WO2002000692A2
(en)
|
2000-06-28 |
2002-01-03 |
Genetics Institute, Llc. |
Pd-l2 molecules: pd-1 ligands and uses therefor
|
|
FR2814642B1
(fr)
|
2000-10-03 |
2005-07-01 |
Ass Pour Le Dev De La Rech En |
Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
|
|
WO2002039813A1
(en)
|
2000-11-15 |
2002-05-23 |
Ono Pharmaceutical Co., Ltd. |
Pd-1-lacking mouse and use thereof
|
|
EP2388590A1
(en)
|
2001-04-02 |
2011-11-23 |
Dana Farber Cancer Institute |
PD-1, a receptor for B7-4, and uses thereof
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
ATE524495T1
(de)
|
2001-07-31 |
2011-09-15 |
Ono Pharmaceutical Co |
Pd-1-spezifische substanz
|
|
EP1456652A4
(en)
|
2001-11-13 |
2005-11-02 |
Dana Farber Cancer Inst Inc |
IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
|
|
DE60334303D1
(de)
|
2002-07-03 |
2010-11-04 |
Tasuku Honjo |
Immunpotenzierende zusammensetzungen
|
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
DK1907000T4
(da)
|
2005-06-08 |
2020-03-30 |
The President And Fellows Of Harvard College |
Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
|
|
ES2547463T3
(es)
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
|
EP2889309B1
(en)
|
2006-03-03 |
2017-12-27 |
Ono Pharmaceutical Co., Ltd. |
Multimer of extracellular domain of pd-1 or pd-l1
|
|
HUE033466T2
(en)
|
2006-10-02 |
2017-12-28 |
Ac Immune Sa |
Humanized antibody to beta-amyloid
|
|
CA2673870A1
(en)
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
|
JP5675109B2
(ja)
|
2007-02-20 |
2015-02-25 |
アナプティスバイオ インコーポレイティッド |
ライブラリーの生成方法及びその使用
|
|
EP2131860B1
(en)
|
2007-03-20 |
2013-12-18 |
Eli Lilly & Company |
Anti-sclerostin antibodies
|
|
CN101687933B
(zh)
|
2007-05-30 |
2015-11-25 |
浦项工科大学校产学协力团 |
免疫球蛋白融合蛋白
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
US20120269806A1
(en)
|
2007-08-21 |
2012-10-25 |
The General Hospital Corporation |
Methods of inducing tolerance
|
|
US8563314B2
(en)
|
2007-09-27 |
2013-10-22 |
Sangamo Biosciences, Inc. |
Methods and compositions for modulating PD1
|
|
AU2008311366B2
(en)
|
2007-10-05 |
2015-03-12 |
Ac Immune S.A. |
Use of anti-amyloid beta antibody in ocular diseases
|
|
EP2240466B1
(en)
|
2008-01-08 |
2015-07-29 |
Merck Sharp & Dohme Limited |
Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US8460886B2
(en)
|
2008-07-04 |
2013-06-11 |
Ono Pharmaceutical Co., Ltd. |
Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EA201500417A1
(ru)
|
2008-08-25 |
2015-11-30 |
Эмплиммьюн, Инк. |
Композиции антагонистов pd-1 и способы применения
|
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
AU2009290543B2
(en)
|
2008-09-12 |
2015-09-03 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
|
|
MX2011005691A
(es)
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Metodos para el tratamiento de infecciones y tumores.
|
|
WO2010089411A2
(en)
|
2009-02-09 |
2010-08-12 |
Universite De La Mediterranee |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
EP3594356A1
(en)
|
2009-11-04 |
2020-01-15 |
Merck Sharp & Dohme Corp. |
Engineered anti-tslp antibody
|
|
US20130089554A1
(en)
|
2009-12-29 |
2013-04-11 |
Emergent Product Development Seattle, Llc |
RON Binding Constructs and Methods of Use Thereof
|
|
US20130202623A1
(en)
|
2010-02-16 |
2013-08-08 |
Nicolas Chomont |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2793309A1
(en)
|
2010-03-17 |
2011-09-22 |
Anaptysbio, Inc. |
Method of producing transcripts using cryptic splice sites
|
|
KR20130031247A
(ko)
*
|
2010-03-17 |
2013-03-28 |
애보트 리서치 비.브이. |
항―신경 성장 인자（ｎｇｆ） 항체 조성물
|
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
|
WO2012021851A2
(en)
|
2010-08-12 |
2012-02-16 |
Beth Israel Deaconess Medical Center |
Methods and compositions for diagnosing and treating lupus
|
|
US20130310266A1
(en)
|
2010-09-03 |
2013-11-21 |
Immport Therapeutics, Inc. |
Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders
|
|
CN103261217B
(zh)
|
2010-11-11 |
2017-04-26 |
港大科桥有限公司 |
可溶性 pd‑1变体、融合构建体及其用途
|
|
WO2012123755A1
(en)
|
2011-03-17 |
2012-09-20 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
WO2012135408A1
(en)
|
2011-03-31 |
2012-10-04 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
|
|
US8609625B2
(en)
|
2011-06-24 |
2013-12-17 |
Taipei Veterans General Hospital |
Method for enhancing immune response in the treatment of infectious and malignant diseases
|
|
BR112014002353B1
(pt)
|
2011-08-01 |
2022-09-27 |
Genentech, Inc |
Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
|
|
WO2013022091A1
(ja)
|
2011-08-11 |
2013-02-14 |
小野薬品工業株式会社 |
Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
US9856320B2
(en)
|
2012-05-15 |
2018-01-02 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
|
|
WO2013177102A2
(en)
|
2012-05-21 |
2013-11-28 |
Felder Mitchell S |
Treatment of cancer by manipulating the immune system
|
|
WO2013174997A1
(en)
|
2012-05-25 |
2013-11-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of refractory haematological malignancies
|
|
ES2742379T3
(es)
|
2012-05-31 |
2020-02-14 |
Hoffmann La Roche |
Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
|
|
RS61400B1
(sr)
*
|
2013-05-02 |
2021-02-26 |
Anaptysbio Inc |
Antitela usmerena protiv programirane smrti-1 (pd-1)
|
|
CR20160319A
(es)
|
2013-12-12 |
2016-11-08 |
Jiangsu Hengrui Medicine Co |
Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
EP3114144A1
(en)
*
|
2014-03-05 |
2017-01-11 |
Bristol-Myers Squibb Company |
Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
CN107172880B
(zh)
|
2014-03-24 |
2021-09-28 |
癌症研究技术有限公司 |
含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
|
|
WO2015196051A1
(en)
|
2014-06-19 |
2015-12-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized programmed cell death 1 gene
|
|
PT3177644T
(pt)
|
2014-08-05 |
2021-01-13 |
MabQuest SA |
Reagentes imunológicos que se ligam a pd-1
|
|
EP3183269A2
(en)
*
|
2014-08-22 |
2017-06-28 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
KR20170066546A
(ko)
|
2014-10-03 |
2017-06-14 |
노파르티스 아게 |
조합 요법
|
|
EP3212233B1
(en)
|
2014-10-31 |
2020-06-24 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
MA41217A
(fr)
|
2014-12-19 |
2017-10-24 |
Advaxis Inc |
Polythérapies ayant des souches de listeria recombinées
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
CA2971734C
(en)
|
2014-12-22 |
2025-11-18 |
Pd-1 Acquisition Group, Llc |
Anti-pd-1 antibodies
|
|
HUE053145T2
(hu)
|
2014-12-31 |
2021-06-28 |
Checkmate Pharmaceuticals Inc |
Kombinált tumor immunterápia
|
|
CA3081058C
(en)
|
2015-01-16 |
2024-02-20 |
Academia Sinica |
Linker units and their uses in configuring pharmaceutical molecules
|
|
MA41463A
(fr)
|
2015-02-03 |
2017-12-12 |
Anaptysbio Inc |
Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
|
|
PL3277321T3
(pl)
|
2015-04-01 |
2024-11-18 |
Anaptysbio, Inc. |
Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
|
|
HRP20201334T1
(hr)
*
|
2015-04-17 |
2020-11-27 |
Bristol-Myers Squibb Company |
Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
|
|
EP3288980B1
(en)
|
2015-04-28 |
2021-03-10 |
Bristol-Myers Squibb Company |
Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
HRP20240136T1
(hr)
|
2016-06-29 |
2024-04-12 |
Tesaro, Inc. |
Metode liječenja raka jajnika
|
|
CN110049777A
(zh)
*
|
2016-11-01 |
2019-07-23 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
|
MA50677A
(fr)
|
2016-11-01 |
2021-07-14 |
Anaptysbio Inc |
Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
|
|
EA201990741A1
(ru)
*
|
2016-11-29 |
2019-11-29 |
|
Антитела, направленные против белка-1 запрограммированной смерти (pd-1)
|
|
PT3565844T
(pt)
|
2017-01-09 |
2023-05-02 |
Tesaro Inc |
Métodos de tratamento de cancro com anticorpos anti-pd-1
|
|
AU2018205401B2
(en)
|
2017-01-09 |
2025-01-02 |
Tesaro, Inc. |
Methods of treating cancer with anti-TIM-3 antibodies
|
|
WO2019067978A1
(en)
|
2017-09-30 |
2019-04-04 |
Tesaro, Inc. |
POLYTHERAPIES FOR THE TREATMENT OF CANCER
|
|
TWI852940B
(zh)
|
2018-09-04 |
2024-08-21 |
美商泰沙羅公司 |
治療癌症之方法
|